Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2024-08-13 07:00:17
Bergen, Norway, 13 August 2024- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, will be announcing its results for the second quarter and
half year 2024 on Wednesday 21 August 2024. The briefing will take place at the
Conference "Vestland på Børs" at 09:45 am CEST where BerGenBio's senior
management team will provide a business update.
The presentation will webcast live, a link will be available at
www.bergenbio.com in the Investors/Financial Reports
section (https://www.bergenbio.com/investors/financial-reports) and a recording
will be available shortly after the webcast has finished. Direct link to the
webcast: BerGenBio Webcast Q2
2024 (https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20240821_12)
The second quarter and half year financial report and presentation will be made
available on the Company's website in the Investors/Financial Reports
section (https://www.bergenbio.com/investors/financial-reports) from 7:00am CEST
the same day.
-End-
Contacts
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Media Relations
Jan Lilleby
jl@lillebyfrisch.no
+47 90 55 16 98
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK.
The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com.
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to MAR
article 17 and section 5-12 of the Norwegian Securities Trading Act.